Clinicopathological studies on the remodeling effect of Platelet-Rich plasma on lung fibrosis induced by amiodarone in Albino rats

Abstract

Objectives: This study aimed to evaluate the role of platelet rich plasma (PRP) in the treatment of lung fibrosis induced by amiodarone drug. Materials and Methods: Seventy adult male Wistar albino rats were divided into three groups (n=20) plus ten rats were used for PRP collection. The first group used as control group. The rats in second group (gp.2) were injected intraperitoneally (i.p.) daily with amiodarone drug at (80 mg/ kg. bwt) for three weeks, then injected (24 hours after last dose of amiodarone) (i.p.) with phosphate buffer saline (PBS) (0.5 ml/ kg. bwt) two times weekly for three weeks. The rats in third group (gp.3) were injected (i.p.) daily with amiodarone drug at (80 mg/ kg. bwt) for three weeks, plus (i.p.) injection with platelet rich plasma (PRP) at dose (0.5 ml/kg. bwt) (24 hours after last dose of amiodarone injection) two times weekly for three weeks. The animals were examined during the experiment and sacrificed at the end of the experiment. Results: Rats in the PRP treatment (gp. 3) showed an increase in the level of WBCs and RBCs counts in comparison with group 2. Significant increase in glutathione reductase and a significant decrease in malondialdehyde levels were detected in group 3 when compared with group 2. The histopathological findings showed an improvement in the fibrosed lungs compared to gp (2). Conclusions: This study concluded the remodeling effect of PRP, which was observed clinically and pathologically against the harmful effects of amiodarone in albino rats.

Platelet-Rich Plasma Treatment for Chronic Respiratory Disease

“…Maher et al did a controlled animal study to assess the efficacy of PRP usage for the treatment of amiodarone-induced pulmonary fibrosis [ 27 ]. Amiodarone, a very useful medication in cardiology, is known to have many adverse effects, including pulmonary fibrosis [ 27 ].…”

“…Maher et al did a controlled animal study to assess the efficacy of PRP usage for the treatment of amiodarone-induced pulmonary fibrosis [ 27 ]. Amiodarone, a very useful medication in cardiology, is known to have many adverse effects, including pulmonary fibrosis [ 27 ]. This trial used 70 adult albino rats in total, divided into three groups, with each group consisting of 20 rats, while 10 rats functioned as PRP donors [ 27 ].…”

“…Amiodarone, a very useful medication in cardiology, is known to have many adverse effects, including pulmonary fibrosis [ 27 ]. This trial used 70 adult albino rats in total, divided into three groups, with each group consisting of 20 rats, while 10 rats functioned as PRP donors [ 27 ]. Group 1 acted as the control group.…”

“…Group 1 acted as the control group. Group 2 (non-PRP) was given amiodarone via intraperitoneal injection daily for three weeks, followed by phosphate-buffered saline (PBS) twice weekly for three weeks via intra-peritoneum [ 27 ]. Group 3 (PRP) had a similar protocol to Group 2: amiodarone daily for three weeks intraperitoneally, followed by PRP twice weekly for three weeks [ 27 ].…”

Plasma rico en plaquetas como terapia autóloga en la medicina regenerativa: Revisión narrativa

“…Estudios de edema inducido experimentalmente por sepsis en ratones, demuestran que el PRP regula la actividad de la quinasa endotelial de la túnica interna y previene la fuga vascular en los pulmones, por lo que se propone su uso terapéutico como regenerador potencial para el síndrome respiratorio agudo inducido por sepsis, así como otras enfermedades con permeabilidad vascular anormal (Mammoto et al, 2015a(Mammoto et al, , 2015b. Un estudio clínicopatológico en ratas albinas en las que se indujo fibrosis pulmonar por amiodarona, demostró que la aplicación de PRP tiene un efecto remodelador de la lesión pulmonar provocada (Maher et al, 2020). El uso de PRP en forma de aerosol ayuda a la regeneración de las vías respiratorias por inhalación y mejora el proceso de convalecencia en pacientes asmáticos de tipo crónico (Salama et al, 2019).…”